Giá Devonian Health Group Inc. (DVHGF)

Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 8 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.